1. Cell virus 07 Virus

2. Virus 構造 DNA or RNA Protein 病毒的區分 依外觀區分 依遺傳物質區分

3. Types of genetic material in different virus Double-stranded DNA Single-stranded DNA Double-stranded RNA Single-stranded RNA (+)sense RNA (-)non-sense RNA

5. Bacterial virus

7. Bacteriophage lambda

9. Influenza virus

10. How are virus get into cells ?

11. Baculovirus 對特定寄主有極高的致病力與專一性，其宿 主侷限於昆蟲及部分甲殼類動物 桿狀病毒包括 核多角病毒（ nuclear polyhedrosis virus ， NPV ） 顆粒體病毒（ granulosis virus ， GV ）

12. Baculovirus ( 續 ) Double-stranded,circular DNA 80-200kb size Accommodate an additional 100kb or more of foreign DNA Two types of virions Polyhedra –derived virion (PDV) Budded virion (BV)

13. Baculovirus ( 續 )

14. Baculovirus 的感染機制

15. HIV

16. HIV 之葯物設計 Zidovudine or azidothymidine (AZT) (also called ZDV) is a nucleoside analog reverse transcriptase inhibitor (NRTI), a type of antiretroviral drug. NRTIs: Zidovudine(AZT) Didanosine(ddI) Zalcitabine(ddC) Lamivudine(3TC) Stavudine(d4T)

17. protease inhibitor : HIV 之葯物設計 Saqunavir(invirase) Ritonavir(norvir) Indinavir(crixivan)

18. 雞尾酒療法 Combinations of antiretrovirals create multiple obstacles to HIV replication to keep the number of offspring low and reduce the possibility of a superior mutation.

19. Food and Drug Administration （ FDA ，美國食品藥物檢驗局） The drug advertising regulation contains two key requirements. Under most circumstances, a company may only advertise a drug for the specific indication or medical use for which it was approved. Also, an advertisement must contain "fair balance" between the benefits and risks of a drug.

20. Clinical trial Pre-clinical studies in vitro (test tube) and in vivo (animal) experiments preliminary efficacy, toxicity and pharmacokinetic information Phase 0 Phase I Phase II Phase III approved Phase IV: Post Marketing Surveillance Trial

21. Clinical trial Pre-clinical studies Phase 0 2006 Distinctive features of Phase 0 trials include the administration of single subtherapeutic doses of the study drug to a small number of subjects (10 to 15) to gather preliminary data on the agent's pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug works in the body).

22. Clinical trial Pre-clinical studies Phase 0 Phase I Normally, a small (20-50) group of healthy volunteers will be selected. This phase includes trials designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. Phase II Phase III

23. Clinical trial Pre-clinical studies Phase 0 Phase I Phase II Phase II trials are performed on larger groups (20-300) and are designed to assess how well the drug works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. Phase III

24. Clinical trial Pre-clinical studies Phase 0 Phase I Phase II Phase III Phase III studies are randomized controlled multicenter trials on large patient groups (300–3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run. approved Phase IV: Post Marketing Surveillance Trial

25. Polioviurs Naked virion (+)single-strand RNA Producing an RNA replicase Polyprotein